NovaDel (NVD) Enters Possible $2M Agreement with Mist Acquisition to Manufacture and Commercialize NitroMist
More News related to NVD
- Novadel Pharma Inc. (NVD) Posts Q3 Loss of 2c, In-Line with Views
- Novadel Pharma Inc. (NVD) Posts Q3 Loss of 2c, In-Line with Views
- NovaDel Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2009
- NovaDel Pharma (NVD) to Enter into Exclusive License and Distribution Agreement with ECR Pharma for ZolpiMist
- NovaDel Signs Exclusive License and Distribution Agreement with Hi-Tech Pharmacal Co., Inc.'s Subsidiary to Commercialize and Manufacture ZolpiMist(TM) in the US and Canada
More News related to Corporate News
- Compellent Technologies (CML) Completes 3.84 Million Share Offering
- Advanced Micro Devices (AMD) To Sell $500M of Senior Notes in Private Offering
- Quaker Chemical (KWR) Files $100M Mixed Shelf
- Double Eagle Petrol (DBLE) Files $200M Mixed Shelf
- Washington Banking Co. (WBCO) Announces $30 Million Common Stock Offering
NovaDel Pharma Inc., (AMEX: NVD) has entered into a licensing agreement with privately-held Mist Acquisition, LLC to manufacture and commercialize the NitroMist lingual spray version of nitroglycerine, a widely-prescribed and leading short-acting nitrate for the treatment of angina pectoris.
Under terms of the agreement, Mist will pay NovaDel a $1 million licensing fee upon execution of the agreement, milestone payments totaling an additional $1 million over the next twelve months and ongoing performance payments of 17% of net sales.
Through a separate license agreement with Mist, Akrimax Pharmaceuticals, LLC will receive the exclusive right to manufacture, distribute, market and sell NitroMist in North America. NitroMist provides acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. The lingual spray form of the drug is conveniently administered and is rapidly absorbed into the bloodstream via the oral mucosa, providing patients a fast and tolerable treatment option for the prevention or relief of pain associated with such attacks.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
